NEW YORK (GenomeWeb News) — Transgenomic said after the close of the market on Wednesday that its first quarter revenues declined 15 percent year over year.

For the three months ended March 31, the Omaha, Neb.-based molecular diagnostics firm logged total revenues of $6.3 million compared to $7.4 million in the prior-year period. Transgenomic attributed this decline primarily to lower sales in its Laboratory Services segment, reflecting higher-than-usual sales in Q1 2013 that had resulted from working down a backlog of Nuclear Mitome tests from 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.